Transactivation of epidermal growth factor receptor in vascular and renal systems in rats with experimental hyperleptinemia: Role in leptin-induced hypertension

Biochemical Pharmacology

Volumn 75, Issue 8, 2008, Pages 1623-1638

  Jamroz Wiśniewska, Anna ^a   Wójcicka, Grazyna ^a   Łowicka, Ewelina ^a   Ksiazek, Marta ^b   Bełtowski, Jerzy ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Regional Hospital Rzeszow   (Poland)

Author keywords

Arterial hypertension; c Src tyrosine kinase; Epidermal growth factor receptor; Extracellular signal regulated kinases; Leptin; Na+,K+ ATPase

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 6,7 DIMETHYL 2 PHENYLQUINOXALINE; ADENOSINE TRIPHOSPHATASE; APOCYNIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EXTRACELLULAR SIGNAL REGULATED KINASE INHIBITOR; HYDROGEN PEROXIDE; ISOPROSTANE; LEPTIN; MANUMYCIN A; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR INHIBITOR; POTASSIUM ION; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; SODIUM ION; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BLOOD VESSEL WALL; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DRUG INHIBITION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HYPERLEPTINEMIA; HYPERTENSION; KIDNEY; MALE; METABOLIC SYNDROME X; NATRIURESIS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; RAT; SODIUM EXCRETION; TREATMENT PLANNING; URINARY EXCRETION;

ANIMALS; AORTA, ABDOMINAL; AORTA, THORACIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GLOMERULAR FILTRATION RATE; HYPERTENSION; ISOPROSTANES; KIDNEY; LEPTIN; MALE; OXIDATIVE STRESS; PROTEIN-TYROSINE KINASES; RATS; RATS, WISTAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; SODIUM; SODIUM-POTASSIUM-EXCHANGING ATPASE;

EID: 40949152762     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.01.003     Document Type: Article

References (63)

1. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 334 (1996) 292-295
2. Agata J., Masuda A., Takada M., Higashiura K., Murakami H., Miyazaki Y., et al. High plasma immunoreactive leptin level in essential hypertension. Am J Hypertens 10 (1997) 1171-1174
3. Shek E.W., Brands M.W., and Hall J.E. Chronic leptin infusion increases arterial pressure. Hypertension 31 (1998) 409-414
4. Aizawa-Abe M., Ogawa Y., Masuzaki H., Ebihara K., Satoh N., Iwai H., et al. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 105 (2000) 1243-1252
5. Mark A.L., Schaffer R.A., Correia M.L.G., Morgan D.A., Sigmund C.D., and Haynes W.G. Contrasting blood pressure effects of obesity in leptin deficient ob/ob mice and agouti yellow obese mice. J Hypertens 17 (1999) 1949-1953
6. Kuo J.J., Jones O.B., and Hall J.E. Inhibition of NO synthesis enhances chronic cardiovascular and renal actions of leptin. Hypertension 37 (2001) 670-676
7. El-Gharbawy A.H., Kotchen J.M., Grim C.E., Kaldunski M., Hoffmann R.G., Pausova Z., et al. Gender-specific correlates of leptin with hypertension-related phenotypes in African Americans. Am J Hypertens 15 (2002) 989-993
8. Bełtowski J., Wójcicka G., Marciniak A., and Jamroz A. Oxidative stress, nitric oxide production, and renal sodium handling in leptin-induced hypertension. Life Sci 74 (2004) 2987-3000
9. Chao H.H., Hong H.J., Liu J.C., Lin J.W., Chen Y.L., Chiu W.T., et al. Leptin stimulates endothelin-1 expression via extracellular signal-regulated kinase by epidermal growth factor receptor transactivation in rat aortic smooth muscle cells. Eur J Pharmacol 573 (2007) 49-54
10. Dong F., Zhang X., and Ren J. Leptin regulates cardiomyocyte contractile function through endothelin-1 receptor-NADPH oxidase pathway. Hypertension 47 (2006) 222-229
11. Knudson J.D., Dick G.M., and Tune J.D. Adipokines and coronary vasomotor dysfunction. Exp Biol Med 232 (2007) 727-736
12. Fernandez-Patron C. Therapeutic potential of the epidermal growth factor receptor transactivation in hypertension: a convergent signaling pathway of vascular tone, oxidative stress, and hypertrophic growth downstream of vasoactive G-protein-coupled receptors?. Can J Physiol Pharmacol 85 (2007) 97-104
13. Eguchi S., Numaguchi K., Iwasaki H., Matsumoto T., Yamakawa T., Utsunomiya H., et al. Calcium-dependent epidermal growth factor receptor transactivation mediates the angiotensin II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells. J Biol Chem 273 (1998) 8890-8896
14. 2-induced transactivation of EGF receptor requires Src and mediates ERK1/2, but not Akt, activation in renal cells. Am J Physiol Renal Physiol 286 (2004) F858-F865
15. Feraille E., and Doucet A. Sodium-potassium-adenosinetriphosphatase-dependent sodium transport in the kidney: hormonal control. Physiol Rev 81 (2001) 345-418
16. +-ATPase in the proximal tubules of obese Zucker rats. Clin Exp Hypertens 28 (2006) 29-40
17. +-ATPase. Peptides 27 (2006) 3234-3244
18. +-ATPase activity in leptin-treated rats. Pharmacol Rep 57 (2005) 219-228
19. Johns T.G., Luwor R.B., Murone C., Walker F., Weinstock J., Vitali A.A., et al. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478. Proc Natl Acad Sci USA 100 (2003) 15871-15876
20. Muthalif M.M., Benter I.F., Khandekar Z., Gaber L., Estes A., Malik S., et al. Contribution of Ras GTPase/MAP kinase and cytochrome P450 metabolites to deoxycorticosterone-salt-induced hypertension. Hypertension 35 (2000) 457-463
21. Sugita M., Sugita H., and Kaneki M. Farnesyltransferase inhibitor, manumycin A, prevents atherosclerosis development and reduces oxidative stress in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 27 (2007) 1390-1395
22. Hao L., Du M., Lopez-Campistrous A., and Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 94 (2004) 68-76
23. Lund L.R., Green K.A., Stoop A.A., Ploug M., Almholt K., Lilla J., et al. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice. EMBO J 25 (2006) 2686-2697
24. Wu W., Graves L.M., Gill G.N., Parsons S.J., and Samet J.M. Src-dependent phosphorylation of the epidermal growth factor receptor on tyrosine 845 is required for zinc-induced Ras activation. J Biol Chem 277 (2002) 24252-24257
25. Hurst R.O. The determination of nucleotide phosphorus with a stannous chloride-hydrazine sulphate reagent. Can J Biochem Physiol 42 (1964) 287-292
26. Yuen J.W., and Benzie I.F. Hydrogen peroxide in urine as a potential biomarker of whole body oxidative stress. Free Radic Res 37 (2003) 1209-1213
27. Lowry O.H., Rosenbrough N.I., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
28. Kubo T., Ibusuki T., Saito E., Kambe T., and Hagiwara Y. Different activation of vascular mitogen-activated protein kinases in spontaneously and DOCA-salt hypertensive rats. Eur J Pharmacol 400 (2000) 231-237
29. Touyz R.M., He G., El Mabrouk M., Diep Q., Mardigyan V., and Schiffrin E.L. Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by AT1 receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats. J Hypertens 19 (2001) 553-559
30. Touyz R.M., He G., Wu X.H., Park J.B., Mabrouk M.E., and Schiffrin E.L. Src is an important mediator of extracellular signal-regulated kinase 1/2-dependent growth signaling by angiotensin II in smooth muscle cells from resistance arteries of hypertensive patients. Hypertension 38 (2001) 56-64
31. Touyz R.M., Deschepper C., Park J.B., He G., Chen X., Neves M.F., et al. Inhibition of mitogen-activated protein/extracellular signal-regulated kinase improves endothelial function and attenuates Ang II-induced contractility of mesenteric resistance arteries from spontaneously hypertensive rats. J Hypertens 20 (2002) 1127-1134
32. Touyz R.M., Wu X.H., He G., Salomon S., and Schiffrin E.L. Increased angiotensin II-mediated Src signaling via epidermal growth factor receptor transactivation is associated with decreased C-terminal Src kinase activity in vascular smooth muscle cells from spontaneously hypertensive rats. Hypertension 39 (2002) 479-485
33. Muthalif M.M., Karzoun N.A., Gaber L., Khandekar Z., Benter I.F., Saeed A.E., et al. Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites. Hypertension 36 (2000) 604-609
34. Laplante M.A., Wu R., El Midaoui A., and de Champlain J. NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERK-MAPK pathway activation in rat's vascular smooth muscle cells. J Hypertens 21 (2003) 927-936
35. Michlig S., Mercier A., Doucet A., Schild L., Horisberger J.D., Rossier B.C., et al. ERK1/2 controls Na, K-ATPase activity and transepithelial sodium transport in the principal cell of the cortical collecting duct of the mouse kidney. J Biol Chem 279 (2004) 51002-51012
36. +-ATPase via activation of ERK1/2 MAP kinases in human renal tubular cells. Cell Mol Life Sci 61 (2004) 2782-2790
37. Berk B.C., Brock T.A., Webb R.C., Taubman M.B., Atkinson W.J., Gimbrone M.A., et al. Epidermal growth factor, a vascular smooth muscle mitogen, induces rat aortic contraction. J Clin Invest 75 (1985) 1083-1086
38. Florian J.A., and Watts S.W. Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Am J Physiol 276 (1999) H976-H983
39. Keiser J.A., and Ryan M.J. Hemodynamic effects of epidermal growth factor in conscious rats and monkeys. Proc Natl Acad Sci USA 93 (1996) 4957-4961
40. +-ATPase activity by a tyrosine phosphorylation process in rat proximal convoluted tubule. J Physiol 498 (1997) 99-108
41. Sambhi M.P., Swaminathan N., Wang H., and Rong H. Increased EGF binding and EGFR mRNA expression in rat aorta with chronic administration of pressor angiotensin II. Biochem Med Metab Biol 48 (1992) 8-18
42. Ebisui O., Dilley R.J., Li H., Funder J.W., and Liu J.P. Growth factors and extracellular signal-regulated kinase in vascular smooth muscle cells of normotensive and spontaneously hypertensive rats. J Hypertens 17 (1999) 1535-1541
43. Northcott C., Florian J.A., Dorrance A., and Watts S.W. Arterial epidermal growth factor receptor expression in deoxycorticosterone acetate-salt hypertension. Hypertension 38 (2001) 1337-1341
44. Ying W.Z., and Sanders P.W. Enhanced expression of EGF receptor in a model of salt-sensitive hypertension. Am J Physiol Renal Physiol 289 (2005) F314-F321
45. Kim J., Lee C.K., Park H.J., Kim H.J., So H.H., Lee K.S., et al. Epidermal growth factor induces vasoconstriction through the phosphatidylinositol 3-kinase-mediated mitogen-activated protein kinase pathway in hypertensive rats. J Pharmacol Sci 101 (2006) 135-143
46. Kagiyama S., Eguchi S., Frank G.D., Inagami T., Zhang Y.C., and Phillips M.I. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 106 (2002) 909-912
47. Singh P., Hoffmann M., Wolk R., Shamsuzzaman A.S., and Somers V.K. Leptin induces C-reactive protein expression in vascular endothelial cells. Arterioscler Thromb Vasc Biol 27 (2007) e302-e307
48. Shida D., Kitayama J., Mori K., Watanabe T., and Nagawa H. Transactivation of epidermal growth factor receptor is involved in leptin-induced activation of janus-activated kinase 2 and extracellular signal-regulated kinase 1/2 in human gastric cancer cells. Cancer Res 65 (2005) 9159-9163
49. 2-terminal kinase activation. Endocrinology 147 (2006) 4505-4516
50. Konturek P.C., Brzozowski T., Sulekova Z., Brzozowska I., Duda A., Meixner H., et al. Role of leptin in ulcer healing. Eur J Pharmacol 414 (2001) 87-97
51. Francois H., Placier S., Flamant M., Tharaux P.L., Chansel D., Dussaule J.C., et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. FASEB J 18 (2004) 926-928
52. Wolf G., and Ziyadeh F.N. Leptin and renal fibrosis. Contrib Nephrol 151 (2006) 175-183
53. Zeidan A., Purdham D.M., Rajapurohitam V., Javadov S., Chakrabarti S., and Karmazyn M. Leptin induces vascular smooth muscle cell hypertrophy through angiotensin II- and endothelin-1-dependent mechanisms and mediates stretch-induced hypertrophy. J Pharmacol Exp Ther 315 (2005) 1075-1084
54. Karmazyn M., Purdham D.M., Rajapurohitam V., and Zeidan A. Leptin as a cardiac hypertrophic factor: a potential target for therapeutics. Trends Cardiovasc Med 17 (2007) 206-211
55. Garofalo C., and Surmacz E. Leptin and cancer. J Cell Physiol 207 (2006) 12-22
56. Park H.Y., Kwon H.M., Lim H.J., Hong B.K., Lee J.Y., Park B.E., et al. Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 33 (2001) 95-102
57. Kelly D.J., Cox A.J., Gow R.M., Zhang Y., Kemp B.E., and Gilbert R.E. Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension 44 (2004) 195-202
58. Azar Z.M., Mehdi M.Z., and Srivastava A.K. Insulin-like growth factor type-1 receptor transactivation in vasoactive peptide and oxidant-induced signaling pathways in vascular smooth muscle cells. Can J Physiol Pharmacol 85 (2007) 105-111
59. Schellings M.W., Baumann M., van Leeuwen R.E., Duisters R.F., Janssen S.H., Schroen B., et al. Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 47 (2006) 467-474
60. Nguyen T.T., Cao N., Short J.L., and White P.J. Intravenous insulin-like growth factor-I receptor antisense treatment reduces angiotensin receptor expression and function in spontaneously hypertensive rats. J Pharmacol Exp Ther 318 (2006) 1171-1177
61. Beltowski J., Wojcicka G., Jamroz-Wisniewska A., and Borkowska E. Role of PI3K and PKB/Akt in acute natriuretic and NO-mimetic effects of leptin. Regul Pept 140 (2007) 168-177
62. Rodriguez A., Fortuno A., Gomez-Ambrosi J., Zalba G., Diez J., and Fruhbeck G. The inhibitory effect of leptin on angiotensin II-induced vasoconstriction in vascular smooth muscle cells is mediated via a nitric oxide-dependent mechanism. Endocrinology 148 (2007) 324-331
63. Nakagawa K., Higashi Y., Sasaki S., Oshima T., Matsuura H., and Chayama K. Leptin causes vasodilation in humans. Hypertens Res 25 (2002) 161-165